> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-3/
- Published: 2019-11-17T12:00:00.000Z
- Updated: 2026-09-14T15:53:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134910

**StemCutis, LLC** says the **Naval Medical Center San Diego** has been added as a second site for the Phase 2 portion of its clinical trial for subjects with cutaneous photoaging, a skin condition caused by chronic ultraviolet radiation sun exposure. According to the company, the clinical trial combines low-dose fractional resurfacing laser treatment on the face with a single intravenous infusion of non-embryonic adult human mesenchymal bone marrow stem cells.

**Quest Diagnostics** has completed acquisition of the outreach laboratory service business of **Clinical Laboratory Partners**, a wholly-owned subsidiary of **Hartford HealthCare,** an integrated health care system with five hospitals in Connecticut. The company says this is the fifth acquisition of a laboratory outreach service business from a hospital system by Quest Diagnostics since 2012.

**Dentsply Sirona** has completed a merger of equals between **Dentsply International**, York, PA and **Sirona Dental Systems**, Salzburg, Austria. It will combine Dentsply’s consumables platform with Sirona’s technology and equipment to provide a wide array of products for dental professionals and labs and enable the treatment of general and specialty procedures including implantology, endodontics and orthodontics, according to the company.

South Korean firm **STC-Stem Cell Treatment & Research Institute** says it has registered a local patent on the method to mass produce its pluripotent stem cells without side effects. It says the technology uses mesenchymal stem cells as source and treats them with a low molecular weight compound derived from a natural compound, which enables mass production of such pluripotent stem cells without side effects while continuing to maintain its functionality.

**Innovate Biopharmaceuticals** has completed an agreement to license all of **Alba Therapeutics’** assets relating to larazotide acetate, a tight junction regulator, a novel oral peptide that has consistently demonstrated, according to the company, the reduction of clinical symptoms of celiac disease in multiple clinical trials. The company says larazotide acetate has the potential to become the first approved medicine to treat celiac disease and has been granted fast-track designation from FDA.